Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Aim: Results from clinical trials support the use of oral antipsychotics for treatment of early or first-episode psychosis in patients with schizophrenia. This paper will review literature on the advantages of early initiation of treatment for schizophrenia and the clinical benefits of early use of long-acting injectable antipsychotics (LAIs).

Method: A comprehensive literature review was conducted to identify published literature on the use of LAIs early in the treatment of schizophrenia.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

Background: A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.